USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TERAPIO
Address:
11412 Bee Cave Rd
Suite 100
AUSTIN, TX 78738-
Phone:
N/A
URL:
EIN:
126388978
DUNS:
806143207
Number of Employees:
11
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $809,128.00 2
SBIR Phase II $3,000,000.00 1

Award List:

Development of RLIP767 as a Radiation Countermeasure

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$559,128.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): A major instigator of radiation-induced pathology is cellular damage caused by reactive oxygen species formed in the first moments after exposure. Most therapeutic agents are free radical scavengers which must be presen t in high concentrations as exposure… More

Development of RLIP76 protein as a Radiation Countermeasure

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Charles C. Cunningham – 512-721-1214
Abstract:
DESCRIPTION (provided by applicant): There remains a critical need for medicines that can counteract the toxic effects of radiation exposure. Terapio is developing a recombinant protein, RLIP76, for use as a radioprotectant for workers, military personnel, or civilians that are either in… More

TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$250,000.00
Agency:
HHS
Principal Investigator:
Charles Cunningham – 512-697-8179
Abstract:
Oral mucositis (OM) is a common side effect in oncology patients receiving radiation treatment. Mucosal breakdown causes pain which leads to increased use of narcotic analgesics and restriction of food intake. OM often progresses to septicemia, increasinghospital stays and costs, and ultimately… More